CD8+ T cell responses induced via Ag targeting to CD169 inhibit the outgrowth of OVA-expressing tumor cells when either OVA protein or only peptide is used [31], indicating that a single MHC class I epitope can be sufficient for the induction of anti-tumor T cell immunity. Here, SIGLEC1 is linked to neoplasm.